Literature DB >> 12027412

Diagnostic, surgical and medical aspect of the midgut carcinoids.

H de Vries1, R C J Verschueren, P H B Willemse, I P Kema, E G E de Vries.   

Abstract

This review covers the incidence, prognosis, diagnosis and treatment of midgut carcinoids with emphasis on the surgical and peri-operative aspects. Midgut carcinoids are rare neuro-endocrine tumours which become manifest once they have metastasized to the liver. Treatment of metastatic disease may include radical resection but is usually palliative. The tumour grows relatively slow. Besides the biochemical effects resulting in the carcinoid syndrome, patients may suffer from mechanical mass effects of the tumour. Medical treatment can alleviate the biochemical effects of the tumour, but has a limited effect on tumour growth. The introduction of octreotide was a milestone in palliation of these symptoms and has led to more aggressive treatment protocols. Treatment aimed at cytoreduction of hepatic metastasis and diminished secretion of bioactive amines may achieve good palliation. Cytoreduction may be performed by means of surgery, hepatic arterial ligation, (chemo)embolization, cryosurgery, radio-frequency ablation, internal radiation or even liver transplantation. The role of these options will be discussed in this review. Copyright 2002 Published by Elsevier Science Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12027412     DOI: 10.1053/ctrv.2001.0239

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  10 in total

1.  Management of gastrointestinal carcinoid tumours - 10 years experience at a district general hospital.

Authors:  Shridhar S Dronamraju; Vickram B Joypaul
Journal:  J Gastrointest Oncol       Date:  2012-06

2.  Radioguided exploration facilitates surgical cytoreduction of neuroendocrine tumors.

Authors:  Yi-Zarn Wang; Anne Diebold; Eugene Woltering; Heather King; J Philip Boudreaux; Lowell B Anthony; Richard Campeau
Journal:  J Gastrointest Surg       Date:  2011-11-22       Impact factor: 3.452

3.  Primary mesenteric carcinoid tumor.

Authors:  In-Soo Park; Bong-Hyeon Kye; Hyun-Sil Kim; Hyung-Jin Kim; Hyeon-Min Cho; Changyoung Yoo; Seong Su Hwang
Journal:  J Korean Surg Soc       Date:  2013-01-29

4.  Development and characterization of a novel in vivo model of carcinoid syndrome.

Authors:  Lindsey N Jackson; L Andy Chen; Shawn D Larson; Scott R Silva; Piotr G Rychahou; Paul J Boor; Jing Li; Gilberto Defreitas; W Lane Stafford; Courtney M Townsend; B Mark Evers
Journal:  Clin Cancer Res       Date:  2009-03-31       Impact factor: 12.531

5.  Surgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumors.

Authors:  John Eriksson; Peter Stålberg; Anders Nilsson; Johan Krause; Christina Lundberg; Britt Skogseid; Dan Granberg; Barbro Eriksson; Göran Akerström; Per Hellman
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

6.  Hepatic metastases of primary jejunal carcinoid tumor: A case report with radiological findings.

Authors:  Serhat Avcu; Ozkan Ozen; Mehmet Deniz Bulut; Aydın Bora
Journal:  N Am J Med Sci       Date:  2009-11

7.  Ingestion of a foreign body unmasks an asymptomatic small bowel carcinoid tumor.

Authors:  Yi-Zarn Wang; Patrick Greiffenstein
Journal:  Clin Pract       Date:  2011-12-30

8.  Fatal Systemic Vasoconstriction in a Case of Metastatic Small-Intestinal NET.

Authors:  Jochen Stenzel; Sebastian Noe; Konstantin Holzapfel; Franziska Erlmeier; Florian Eyer
Journal:  Case Rep Gastrointest Med       Date:  2017-07-18

Review 9.  Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas.

Authors:  Bryan Oronsky; Patrick C Ma; Daniel Morgensztern; Corey A Carter
Journal:  Neoplasia       Date:  2017-11-05       Impact factor: 5.715

10.  Comparison of 24-h and overnight samples of urinary 5-hydroxyindoleacetic acid in patients with intestinal neuroendocrine tumors.

Authors:  Merete Gedde-Dahl; Espen Thiis-Evensen; Andreas Myklebust Tjølsen; Kjerstin Skrede Mordal; Morten Vatn; Deidi S Bergestuen
Journal:  Endocr Connect       Date:  2013-01-25       Impact factor: 3.335

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.